959 related articles for article (PubMed ID: 16612464)
1. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
[TBL] [Abstract][Full Text] [Related]
2. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.
Zuardi AW; Crippa JA; Hallak JE; Bhattacharyya S; Atakan Z; Martin-Santos R; McGuire PK; Guimarães FS
Curr Pharm Des; 2012; 18(32):5131-40. PubMed ID: 22716160
[TBL] [Abstract][Full Text] [Related]
3. Medical use of cannabis. Cannabidiol: a new light for schizophrenia?
Deiana S
Drug Test Anal; 2013 Jan; 5(1):46-51. PubMed ID: 23109356
[TBL] [Abstract][Full Text] [Related]
4. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
Schier AR; Ribeiro NP; Silva AC; Hallak JE; Crippa JA; Nardi AE; Zuardi AW
Braz J Psychiatry; 2012 Jun; 34 Suppl 1():S104-10. PubMed ID: 22729452
[TBL] [Abstract][Full Text] [Related]
5. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
6. Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects.
Breuer A; Haj CG; Fogaça MV; Gomes FV; Silva NR; Pedrazzi JF; Del Bel EA; Hallak JC; Crippa JA; Zuardi AW; Mechoulam R; Guimarães FS
PLoS One; 2016; 11(7):e0158779. PubMed ID: 27416026
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of the antipsychotic properties of cannabidiol in humans.
Iseger TA; Bossong MG
Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
[TBL] [Abstract][Full Text] [Related]
8. Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol.
Gomes FV; Llorente R; Del Bel EA; Viveros MP; López-Gallardo M; Guimarães FS
Schizophr Res; 2015 May; 164(1-3):155-63. PubMed ID: 25680767
[TBL] [Abstract][Full Text] [Related]
9. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.
Zuardi AW
Braz J Psychiatry; 2008 Sep; 30(3):271-80. PubMed ID: 18833429
[TBL] [Abstract][Full Text] [Related]
10. Safety and side effects of cannabidiol, a Cannabis sativa constituent.
Bergamaschi MM; Queiroz RH; Zuardi AW; Crippa JA
Curr Drug Saf; 2011 Sep; 6(4):237-49. PubMed ID: 22129319
[TBL] [Abstract][Full Text] [Related]
11. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
Roser P; Vollenweider FX; Kawohl W
World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):208-19. PubMed ID: 20218784
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.
Mandolini GM; Lazzaretti M; Pigoni A; Oldani L; Delvecchio G; Brambilla P
Epidemiol Psychiatr Sci; 2018 Aug; 27(4):327-335. PubMed ID: 29789034
[TBL] [Abstract][Full Text] [Related]
13. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.
Elsaid S; Kloiber S; Le Foll B
Prog Mol Biol Transl Sci; 2019; 167():25-75. PubMed ID: 31601406
[TBL] [Abstract][Full Text] [Related]
14. Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials.
Silvestro S; Mammana S; Cavalli E; Bramanti P; Mazzon E
Molecules; 2019 Apr; 24(8):. PubMed ID: 31013866
[TBL] [Abstract][Full Text] [Related]
15. Cannabidiol as a potential treatment for psychosis.
Schubart CD; Sommer IE; Fusar-Poli P; de Witte L; Kahn RS; Boks MP
Eur Neuropsychopharmacol; 2014 Jan; 24(1):51-64. PubMed ID: 24309088
[TBL] [Abstract][Full Text] [Related]
16. Does cannabidiol have a role in the treatment of schizophrenia?
Gururajan A; Malone DT
Schizophr Res; 2016 Oct; 176(2-3):281-290. PubMed ID: 27374322
[TBL] [Abstract][Full Text] [Related]
17. Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors.
Rodrigues da Silva N; Gomes FV; Sonego AB; Silva NRD; Guimarães FS
Pharmacol Res; 2020 Jun; 156():104749. PubMed ID: 32151683
[TBL] [Abstract][Full Text] [Related]
18. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.
Crippa JA; Guimarães FS; Campos AC; Zuardi AW
Front Immunol; 2018; 9():2009. PubMed ID: 30298064
[No Abstract] [Full Text] [Related]
19. The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.
Hahn B
Schizophr Bull; 2018 Jan; 44(1):46-53. PubMed ID: 29083450
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia.
Levin R; Almeida V; Peres FF; Calzavara MB; da Silva ND; Suiama MA; Niigaki ST; Zuardi AW; Hallak JE; Crippa JA; Abílio VC
Curr Pharm Des; 2012; 18(32):4960-5. PubMed ID: 22716146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]